Clinical Trial Update: Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating parametric cardiac 18F-flutemetamol PET imaging in transthyretin amyloid cardiomyopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• VIZAMYL (Flutemetamol F-18)

Snippet

Sponsor: Yale University | Conditions: Cardiomyopathies, Primary | Phase 1 | Status: COMPLETED